| Article | Date | Source |
|---|
| Undaunted by Wall Street “Penalty Box,” Keryx Focuses on Kidney Drug | May 22, 2012 | Xconomy Life Sciences |
| Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress | May 21, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference | May 10, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Upcoming Poster Presentations of Zerenex™ (ferric citrate) at National Kidney Foundation (NKF) 2012 Spring Clinical Meetings | May 09, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results | May 08, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results | May 07, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Reversion of KRX-0401 (Perifosine) License Rights to Aeterna Zentaris | May 07, 2012 | Pharma News - PR Newswire |
| Keryx rises as Zerenex succeeds in Japan study | April 23, 2012 | Health News - CNBC |
| Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical | April 23, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Top-Line Data from the Perifosine (KRX-0401) X-PECT Phase 3 Clinical Trial | April 02, 2012 | Clinical Trials - PR Newswire |
| As Keryx Biopharmaceuticals, AEterna Zentaris Shares Surge, Investing Writer's Credibility Questioned | March 06, 2012 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results | February 28, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals to Present at Citi's 2012 Global Health Care Conference | February 21, 2012 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference | February 08, 2012 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference | January 04, 2012 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkin's Lymphoma Presented at ASH Meeting | December 13, 2011 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Upcoming Presentations on KRX-0401 (Perifosine) at 53rd Annual Meeting of American Society of Hematology | December 05, 2011 | Clinical Trials - PR Newswire |
| Geron Corporation and Keryx Biopharmaceuticals Making Ground in Lucrative Cancer Drug Market | November 29, 2011 | Biotechnology - Moreover |
| Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting | November 14, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting | November 09, 2011 | Biotech News - PR Newswire |
| Volatility Grows in Biotech Sector -- Keryx and AVI BioPharma Need to Put Up Results | October 21, 2011 | Biotechnology - Moreover |
| Keryx Biopharmaceuticals Release: Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the | October 13, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Release: Publishes Phase 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Capecitabine in Patients with Metastatic Colorectal Cancer | October 06, 2011 | BioSpace - Breaking News |
| Keryx Stock Hits New 52-Week Low (KERX) | September 29, 2011 | Pharmaceutical - Moreover |
| Orexigen and Keryx Grind Though Strict Regulatory Process | September 27, 2011 | Marketwire - Pharma and Biotech |
| Keryx Stock Falls On Unusually High Volume (KERX) | September 19, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study | September 19, 2011 | Biotech News - PR Newswire |
| Late-Stage Products From BioSante and Keryx Gaining Momentum | September 06, 2011 | Marketwire - Pharma and Biotech |
| Keryx reports net loss of $3.1 million for second quarter 2011 | August 08, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results | August 08, 2011 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals (KERX) to Host Conference Call on Second Quarter | August 06, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals (KERX) to Host Conference Call on Second Quarter 2011 Financial Results | August 05, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals to Host Conference Call on Second Quarter 2011 Financial Results | August 05, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results Investor Conference Call to be held Monday, August 8, 2011 at 8:30am EDT | August 04, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results | August 04, 2011 | Biotech News - PR Newswire |
| Oncothyreon and Keryx Look to Benefit From Positive FDA Trends | August 04, 2011 | Biotechnology - Moreover |
| Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study | July 27, 2011 | Biotech News - PR Newswire |
| Cell Therapeutics and Keryx Benefit From Increased Industry Awareness | June 09, 2011 | Marketwire - Pharma and Biotech |
| Keryx Biopharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference | June 06, 2011 | Biotech News - PR Newswire |
| CORRECTING and REPLACING Rodman & Renshaw Acts as a Co-Manager to Keryx Biopharmaceuticals, Inc. in Common Stock Offering | May 04, 2011 | Biotech News - Business Wire |
| Rodman & Renshaw Acts as a Co-Manager to Keryx Biopharmaceuticals, Inc. in Common Stock Offering | May 04, 2011 | Biotech News - Business Wire |
| Keryx Biopharmaceuticals Prices Common Stock Offering | May 04, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering | May 04, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate Zerenex in Japan by Partner, Japan Tobacco and Torii... | May 03, 2011 | Pharmaceutical - Moreover |
| Keryx says more EU kidney drug trials unneeded | May 02, 2011 | Health News - CNBC |
| Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Evaluation Agency for Zerenex(TM) in Hyperphosphatemia | May 02, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Agency for Zerenex™ in Hyperphosphatemia | May 02, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results | April 29, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals To Host Conference Call on First Quarter 2011 Financial Results | April 29, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex Short-Term Phase 3 Study | April 29, 2011 | BioSpace |
| Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results | April 28, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study | April 28, 2011 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals Announces Commencement Of Phase 3 Program Of Ferric Citrate (Zerenex) | April 20, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical | April 19, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate in Japan | April 18, 2011 | Pharmaceutical - Moreover |
| Keryx (KERX) Japanese Partner Commences Ferric Citrate Phase 3 | April 18, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex�) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical (PRN) | April 18, 2011 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical | April 18, 2011 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Results on KRX-0401 (Perifosine) at American Association for Cancer Research Annual Meeting | April 05, 2011 | Clinical Trials - PR Newswire |
| Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research Annual Meeting | March 28, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting | March 28, 2011 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results | March 08, 2011 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET | March 07, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex(TM) Short-Term Phase 3 Data at the Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings | March 07, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings | March 07, 2011 | Biotech News - PR Newswire |
| In-Depth Research Featuring Keryx Biopharmaceuticals and Jazz Pharmaceuticals, Inc. - A Brighter Decade Ahead for Biotech | March 01, 2011 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference | February 09, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. (KERX) – Two Promising Phase III Compounds | January 28, 2011 | Biotechnology - Moreover |
| Keryx Biopharmaceuticals to Present at 29th Annual Healthcare Conference | January 04, 2011 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference | January 04, 2011 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals: Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma | December 06, 2010 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Announces Poster Presentations of KRX-0401 (Perifosine) at the 52nd Annual Meeting of the American Society of Hematology | December 02, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals reports highly statistically significant positive results from phase 3 study of Zerenex | December 01, 2010 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals to Hold Conference Call to Discuss Top-Line Results from Zerenex(TM) Phase 3 Short-Term Study | November 30, 2010 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Kidney-Related Drug, Zerenex Meets Main Goal In Late-Stage Trial | November 30, 2010 | BioSpace |
| Keryx ($KERX) claims a front-line victory with PhIII Zerenex data | November 30, 2010 | FierceBiotech |
| Keryx drug candidate meets late-stage study goal | November 30, 2010 | Health News - CNBC |
| Keryx Biopharmaceuticals Announces Highly Statistically Significant Positive Results From Phase 3 Study of Zerenex™ (Ferric Citrate) for the Treatment of Hyperphosphatemia in Dialysis Patients | November 30, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:30 AM ET to Discuss Top-Line Results from Zerenex™ Phase 3 Short-Term Study | November 29, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference | November 15, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results | November 04, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2010 Financial Results | November 03, 2010 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals to Present at Oppenheimer's 21st Annual Healthcare Conference | October 28, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study | October 26, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference | October 19, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Initiates Long-Term Study Component of Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease on Dialysis | September 29, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference | September 27, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference | September 20, 2010 | Biotech News - PR Newswire |
| Keryx ramps up spending, posts 2Q loss | August 09, 2010 | Health News - CNBC |
| Keryx Biopharmaceuticals Into Q2 Loss On Absence Of Revenues, Higher Research Costs - Update | August 08, 2010 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2010 Financial Results | August 08, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2010 Financial Results | August 05, 2010 | Biotech News - PR Newswire |
| LifeSci Advisors, LLC (LSA) Initiates Coverage on Keryx Biopharmaceuticals (KERX) | August 02, 2010 | Pharmaceutical - Moreover |
| LifeSci Advisors Initiates Coverage on Keryx Biopharmaceuticals | August 02, 2010 | Pharma News - Business Wire |
| Keryx names former Pfizer executive to board | July 21, 2010 | Health News - CNBC |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors | July 21, 2010 | Biotech News - PR Newswire |
| Keryx's shares rally on new orphan drug title for perifosine | July 15, 2010 | FierceBiotech |
| Keryx's perifosine gets second orphan drug status | July 15, 2010 | Health News - CNBC |
| Calls Purchased on Keryx Biopharma (KERX) | July 14, 2010 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Receives Orphan Drug Designation for KRX-0401 (Perifosine) for the Treatment of Neuroblastoma | July 14, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the Upcoming 12th World Congress on Gastrointestinal Cancer | June 29, 2010 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colorectal Cancer | June 08, 2010 | BioSpace - Breaking News |
| Keryx Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colorectal Cancer | June 08, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma | June 07, 2010 | Pharma News - PR Newswire |
| Spotlight on Anadys, Keryx as biotechs' shares trade higher | May 22, 2010 | Pharmaceutical - Moreover |
| Anadys, Keryx trade higher in largely flat sector | May 21, 2010 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals Announces Presentation of Two Abstracts at ASCO 2010 Annual Meeting | May 21, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations | May 14, 2010 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2010 Financial Results | May 10, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2010 Financial Results | May 10, 2010 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals Initiates Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Patients with Hyperphosphatemia | May 06, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Preclinical Activity of Single-Agent KRX-0401 (Perifosine) at 2010 AACR Annual Meeting | April 20, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Reports Updated Long-Term Data of Zerenex (ferric citrate) Presented at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings | April 15, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of Zerenex (ferric citrate) at National Kidney Foundation Conference | April 13, 2010 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of Zerenex (ferric citrate) at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings | April 13, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Refractory Advanced Colorectal Cancer | April 08, 2010 | Clinical Trials - PR Newswire |
| Keryx Gets Fast-Track Status for Perifosine | April 05, 2010 | Health News - Fox Business |
| Keryx Biopharmaceuticals Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer | April 05, 2010 | BioSpace - Breaking News |
| Keryx shares spike as cancer drug wins fast track | April 05, 2010 | FierceBiotech |
| Keryx cancer treatment gets faster FDA review | April 05, 2010 | Health News - CNBC |
| Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer | April 05, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Takes Bigger Loss ($4.7 Million) As Research Spending Grows | March 25, 2010 | BioSpace |
| Keryx takes bigger loss as research spending grows | March 24, 2010 | Health News - CNBC |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2009 Financial Results | March 24, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. To Hold Conference Call on Fourth Quarter and Year-End 2009 Financial Results on Thursday, March 25, 2010 at 8:30 a.m. EDT | March 23, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference | March 10, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference | March 05, 2010 | Pharma News - PR Newswire |
| Rodman & Renshaw Starts Keryx (KERX) at Market Outperform, $6 Price Target | March 01, 2010 | Pharmaceutical - Moreover |
| Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer | February 05, 2010 | Marketwire - Pharma and Biotech |
| AEterna Zentaris Partner Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer | February 03, 2010 | BioSpace - Breaking News |
| Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer | February 03, 2010 | Medical Pharma - PR Newswire |
| Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer | February 03, 2010 | Clinical Trials - PR Newswire |
| Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference | February 02, 2010 | Pharma News - PR Newswire |
| AEterna Zentaris Partner Keryx Biopharmaceuticals Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia | January 29, 2010 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia | January 29, 2010 | Biotech News - PR Newswire |
| Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia | January 29, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer | January 27, 2010 | Biotech News - PR Newswire |
| Keryx Cancer Drug Has Successful Mid-Stage Trial | January 25, 2010 | Health News - Fox Business |
| Keryx Biopharmaceuticals Cancer Drug Improves Survival in Mid-stage Trial | January 25, 2010 | BioSpace |
| Keryx shares surge on promising colon cancer data | January 25, 2010 | FierceBiotech |
| Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer | January 25, 2010 | Pharma News - PR Newswire |
| Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer | January 25, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium | January 21, 2010 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals to Present at the J.P. Morgan 28th Annual Healthcare Conference | January 07, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in the Treatment of Hyperphosphatemia | January 05, 2010 | Pharma News - PR Newswire |
| Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in the Treatment of Hyperphosphatemia | January 05, 2010 | Pharma News - PR Newswire |
| AEterna Zentaris Partner, Keryx Biopharmaceuticals, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma | December 16, 2009 | BioSpace - Breaking News |
| Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma | December 16, 2009 | Biotech News - PR Newswire |
| Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology | December 07, 2009 | Biotech News - PR Newswire |
| Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma | December 02, 2009 | Pharma News - PR Newswire |
